Lincoln National Corp Biomarin Pharmaceutical Inc Transaction History

Lincoln National Corp

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 05, 2021	SELL	$74.77 - $85.47 $256,461 - $293,162	-3,430 Closed	0 $0
Q2 2021 Aug 13, 2021	SELL	$75.51 - $84.79 $2,189 - $2,458	-29 Reduced 0.84%	3,430 $286,000
Q1 2021 May 10, 2021	BUY	$74.73 - $90.69 $8,967 - $10,882	120 Added 3.59%	3,459 $261,000
Q3 2020 Nov 09, 2020	SELL	$71.87 - $131.03 $28,748 - $52,412	-400 Reduced 10.7%	3,339 $254,000
Q2 2020 Jul 31, 2020	SELL	$79.55 - $124.22 $42,957 - $67,078	-540 Reduced 12.62%	3,739 $461,000
Q4 2019 Feb 07, 2020	BUY	$64.27 - $86.37 $275,011 - $369,577	4,279 New	4,279 $362,000
Q1 2018 May 09, 2018	SELL	$77.67 - $92.63 $303,689 - $362,183	-3,910 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$80.76 - $95.13 $315,771 - $371,958	3,910	3,910 $349,000

632

185M

1.63M

1.2M

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $13.1B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

Get notified when there are updates to the investment portfolio of Lincoln National Corp, based on Form 13F filings with the SEC.

Stay updated on Lincoln National Corp with notifications on news.